MG63 and MC3T3-E1 osteoblastic cell lines response to raloxifene

European Journal of Inflammation

Volumn 11, Issue 3, 2013, Pages 797-804

  Lo Muzio, Lorenzo ^a   Santarelli, A ^b,c   Orsini, G ^b   Meme, L ^b   Mattioli Belmonte, M ^b   De Florio, I ^a,d   Gatto, R ^d   Gallusi, G ^d   Nocini, P F ^e   Bertossi, D ^e   Emanuelli, M ^b   Putignano, A ^b   Bambini, F ^b,c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Italian National Institute for Research and Care on Aging   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

MC3T3 E1; MG63; Osteoblasts; Raloxifene

Indexed keywords

ALKALINE PHOSPHATASE; RALOXIFENE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MG63 CELL STRAIN; NONHUMAN; OSTEOLYSIS; TREATMENT RESPONSE;

EID: 84893011790     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727x1301100322     Document Type: Article

References (29)

1. Yamaguchi M, Weitzmann MN. The estrogen 17beta-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-kappaB activity. Int J Mol Med 2009; 23:297-301.
2. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976; 1:1038-41.
3. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984; 311:1273-5. (Pubitemid 15203470)
4. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618-29. (Pubitemid 36210865)
5. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32:1031-6. (Pubitemid 13193215)
6. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11:835-42. (Pubitemid 26172808)
7. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon R Functional domains of the human estrogen receptor. Cell 1987; 51:941-51.
8. Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994; 9:715-24. (Pubitemid 24130473)
9. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994; 134:2283-8. (Pubitemid 24142974)
10. Bambini F, Pellecchia M, Meme L, Santarelli A, Emanuelli M, Procaccini M, Lo Muzio L. Anti-inflammatory cytokines in peri-implant soft tissues: a preliminary study on humans using cDNA microarray technology. Eur J Inflamm 2007; 5:121-7. (Pubitemid 350090682)
11. Xu C,Wang Y,Yu X,Chen X,Li X,Yang X,Li S,Zhang X, Xiang AP. Evaluation of human mesenchymal stem cells response to biomimetic bioglass-collagen- hyaluronic acid-phosphatidylserine composite scaffolds for bone tissue engineering. J Biomed Mater Res A 2009; 88:264-73.
12. Barboza EP, Caula AL, Caula Fde O, de Souza RO, Geolas Neto L, Sorensen RG, Li XJ, Wikesjo UM. Effect of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge with space-providing biomaterials on the augmentation of chronic alveolar ridge defects. J Periodontol 2004; 75:702-8. (Pubitemid 38811861)
13. Bambini F, De Stefano CA, Giannotti L, Meme L, Pellecchia M. Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT). Minerva Stomatol 2003; 52:331-8.
14. Ahola M, Rich J, Kortesuo P, Kiesvaara J, Seppala J, Yli-Urpo A. In vitro evaluation of biodegradable epsilon-caprolactone-co-D, L-lactide/silica xerogel composites containing toremifene citrate. Int J Pharm 1999; 181:181-91. (Pubitemid 29229805)
15. Bambini F, Greci L, Meme L, Santarelli A, Carinci F, Pezzetti F, Procaccini M, Lo Muzio L. Raloxifene covalently bonded to titanium implants by interfacing with (3-aminopropyl)-triethoxysilane affects osteoblast-like cell gene expression. Int J Immunopathol Pharmacol 2006; 19:905-14. (Pubitemid 46150920)
16. Bambini F, Santarelli A, Marzo G, Rubini C, Orsini G, Di Iorio D, Lo Russo L, Lo Muzio L. CD3 and CD20 expression in titanium vs zirconia peri-implant soft tissues: a human study. Eur J Inflamm 2013; 11:305-10.
17. Lo Muzio L, Sartini D, Santarelli A, Rocchetti R, Morganti S, Pozzi V, Rubini C, Emanuelli M. Expression and prognostic significance of apoptotic genes in oral squamous cell carcinoma. Mol Carcinogen 2012 doi: 10.1002/mc.21960.
18. Peterson WJ, Tachiki KH, Yamaguchi DT. Serial passage of MC3T3-E1 cells down-regulates proliferation during osteogenesis in vitro. Cell Prolif 2004; 37:325-36. (Pubitemid 39281183)
19. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002; 30:368-76. (Pubitemid 34150159)
20. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999; 73:500-7. (Pubitemid 29256939)
21. Ernst M, Schmid C, Froesch ER. Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci USA 1988; 85:2307-10. (Pubitemid 24315880)
22. McCarthy TL, Clough ME, Gundberg CM, Centrella M. Expression of an estrogen receptor agonist in differentiating osteoblast cultures. Proc Natl Acad Sci USA 2008; 105:7022-27. (Pubitemid 351754523)
23. Michael H, Harkonen PL, Kangas L, Vaananen HK, Hentunen TA. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007; 151:384-95. (Pubitemid 46842673)
24. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 2003; 177:423-33 (Pubitemid 36722298)
25. Messalli EM, Mainini G, Scaffa C, Cafiero A, Salzillo PL, Ragucci A, Cobellis L. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 2007; 56:38-44. (Pubitemid 44894788)
26. Viereck V, Grundker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003; 88:4206-13. (Pubitemid 37153721)
27. Yan M, Xu Y, Gong Y, Liu J, Lu S, Huang L, Wang Z, Zhao Y, Pang X. Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism. Endocr 2010; 37:55-61.
28. Ball LJ, Levy N, Zhao X, et al. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 2009; 299:204-11.
29. Giner M, Rios MJ, Montoya MJ, Vázquez MA, Miranda C, Pérez-Cano R. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. Eur J Pharmacol 2011; 650:682-87